Jefferies Financial Group Inc. Gilead Sciences, Inc. Call Options Transaction History

Jefferies Financial Group Inc.

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 13, 2024	BUY	$63.15 - $72.88 $473,625 - $546,600	7,500 Added 13.09%	64,800 $4.45 Million
Q1 2024 May 13, 2024	SELL	$71.58 - $87.29 $644,220 - $785,610	-9,000 Reduced 13.57%	57,300 $4.2 Million
Q4 2023 Feb 13, 2024	SELL	$73.27 - $83.09 $5.28 Million - $5.98 Million	-72,000 Reduced 52.06%	66,300 $5.37 Million
Q3 2023 Nov 14, 2023	BUY	$73.94 - $80.67 $5.9 Million - $6.44 Million	79,800 Added 136.41%	138,300 $10.4 Million
Q2 2023 Aug 14, 2023	BUY	$76.01 - $86.7 $266,035 - $303,450	3,500 Added 6.36%	58,500 $4.51 Million
Q1 2023 May 15, 2023	SELL	$77.31 - $88.08 $1.88 Million - $2.14 Million	-24,300 Reduced 30.64%	55,000 $4.56 Million
Q4 2022 Sep 21, 2023	BUY	$62.32 - $89.47 $1.3 Million - $1.86 Million	20,800 Added 35.56%	79,300 $6.81 Million
Q4 2022 Feb 14, 2023	BUY	$62.32 - $89.47 $4.94 Million - $7.09 Million	79,300 New	79,300 $6.81 Million

1,931

991M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $113B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

Stay updated on Jefferies Financial Group Inc. with notifications on news.